Intramuscular Injections of Risperidone 4-Week Long-Acting Injectable (LAI) Formulation in the Buttock of Subjects With Schizophrenia

This study is currently recruiting participants.

Study NCT00821600. Last updated on January 13, 2009.

Information provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Contacts

Contact: Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions:

Locations

United States, California
	Not yet recruiting
Cerritos, California, United States, 90703
	Not yet recruiting
Santa Ana, California, United States, 92701
United States, Georgia
	Recruiting
Atlanta, Georgia, United States, 30308

Sponsors and Collaborators

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Investigators

Study Director:

Johnson & Johnson Pharmaceutical Research and Development, L.L.C. Clinical Trial

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.